Alterity Therapeutics Limited
Ticker(s):
ATHE and PRNAF
Country:
Sector & Industry:
Business Overview
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Contact & Other Information
Number of Employees:
10
Website:
,
,
JPMorgan Chase & Co. became a substantial holder in Alterity Therapeutics Ltd, acquiring a 5.13% voting power.
03/14/2025 | 6-K | 0001213900-25-023838 |Alterity Therapeutics Limited is applying for quotation of 161 ordinary fully paid securities on the ASX due to options being exercised.